Skip to main content

$0.091 0.002 (2.25%)

High

$0.10

Low

$0.09

Trades

2,797

Turnover

$4,713,392

Volume

50,159,971
30 June 2023 at 4:59pm
Register to track IMU and receive email alerts.
Subject
IMU Ann: Results of Meeting

IMU Ann: AGM Presentation

IMU Ann: Imugene Investor Presentation

IMU Ann: Imugene onCARlytics with Estrella ARTEMIS T Cells SITC

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Dose escalates In Phase I Clinical Trial of New Oncolytic Vi

IMU Ann: Imugene onCARlytics with blinatumomab SITC presentation

IMU Ann: Imugene onCARlytics with Celularity CyCART-19 T Cells SITC

IMU Ann: Change of Director's Interest Notice - JE & CW

IMU Ann: AGM ATTENDANCE

IMU Ann: ALA: Europe Patent granted for iNKT Cell Therapy Platform

IMU Ann: Notice Under Section 708A

IMU Ann: Application for quotation of securities - IMU

IMU Ann: First patient dosed in VAXINIA intratumoral cohort 2

IMU Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Letter to IMUOC Optionholders

IMU Ann: Release of Shares from Escrow

IMU Ann: ABL and Imugene partner to advance VAXINIA manufacturing

IMU Ann: Notice of Annual General Meeting/Proxy Form

IMU Ann: Application for quotation of securities - IMU

IMU Ann: HERIZON study results to be featured at ESMO Asia Congress

IMU Ann: onCARlytics to be showcased in three abstracts at SITC

IMU Ann: Imugene appoints Paul Wright as Vice President CMC

IMU Ann: Imugene appoints Dr Giovanni Selvaggi as CMO

IMU Ann: ALA iNKT therapy and IMU onCARlytics - correction

IMU Ann: ALA: Investor Presentation Imugene Arovella Therapies

IMU Ann: Preclinical trial of ALA iNKT therapy and IMU onCARlytics

IMU Ann: First patient IV dosed in VAXINIA Phase 1 clinical trial

IMU Ann: Notification regarding unquoted securities - IMU

IMU Ann: Notice Under Section 708A

IMU Ann: Application for quotation of securities - IMU

IMU Ann: OGTR grants VAXINIA DIR licence allowing trial expansion

IMU Ann: Prospectus for the issue of institutional placement options

IMU Ann: Proposed issue of securities - IMU

IMU Ann: IMUGENE ANNOUNCES A$80 MILLION INSTITUTIONAL PLACEMENT

IMU Ann: Trading Halt

IMU Ann: Imugene doses first patient in nextHERIZON Phase 2 trial

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Initial Director's Interest Notice - JD

IMU Ann: Imugene appoints Dr Jakob Dupont as Non-Executive Director

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Release of Shares from Escrow

IMU Ann: Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA

IMU Ann: Environmental Social and Governance (ESG) Report

IMU Ann: Corporate Governance Statement

IMU Ann: Appendix 4G

IMU Ann: Annual Report and Appendix 4E

IMU Ann: FIRST COHORT 3 PATIENT DOSED IN CLINICAL TRIAL OF CHECKVACC

Register to track IMU and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
MSB
OPT
PAR
PYC
RAC
TLX